stockrowSELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.0 million.
- EPS
- +28.6%
- Free cash flow
- −3.52%
Quarter to June 2026, against a year earlier
Follow SLS
Alert me
SELLAS Life Sciences Group, Inc. (SLS) EV/Sales
As of 6 November 2026, SELLAS Life Sciences Group, Inc. (SLS) trades at a EV/Sales of 136×. Over the past ten years it has ranged from 0.0× (December 2020) to 265× (August 2026); the current reading is higher than 97% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | 3.1× | (43.34%) |
| FY2021 | 5.5× | 250.42% |
| FY2020 | 1.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2022 | 8.8× | (25.93%) |
| Jun 2021 | 11.9× | 38.32% |
| Mar 2021 | 8.6× | 448.08% |
| Dec 2020 | 1.6× | — |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BRVE Braveheart Bio, Inc. compare | n/m |
| KLRA Kailera Therapeutics, Inc. compare | n/m |
| NRIX Nurix Therapeutics, Inc. compare | 0.9× |
| RARE Ultragenyx Pharmaceutical Inc. compare | 1.8× |
| NVAX Novavax, Inc. compare | 3.3× |
| NTLA Intellia Therapeutics, Inc. compare | 20.9× |
| GENB Generate Biomedicines, Inc. compare | 37.2× |
| SLS SELLAS Life Sciences Group, Inc. | 136× |
| ABSI Absci Corporation compare | 896× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)